Global HER2 ADC Drugs 麻豆原创 Growth 2024-2030

Publication ID:

LPI11240107

Publication Date:

November 15, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The HER2-targeted antibody鈥揹rug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) represent a novel class of therapeutics in breast cancer. These drugs augment monoclonal antibodies with a cytotoxic payload, which is attached by a linker, forming the basic structure of an ADC.
The global HER2 ADC Drugs market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淗ER2 ADC Drugs Industry Forecast鈥� looks at past sales and reviews total world HER2 ADC Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected HER2 ADC Drugs sales for 2024 through 2030. With HER2 ADC Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world HER2 ADC Drugs industry.
This Insight Report provides a comprehensive analysis of the global HER2 ADC Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on HER2 ADC Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global HER2 ADC Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for HER2 ADC Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global HER2 ADC Drugs.
United States market for HER2 ADC Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for HER2 ADC Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for HER2 ADC Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key HER2 ADC Drugs players cover Daiichi Sankyo, Genentech, Inc.(Roche), AstraZeneca, RemeGen, MacroGenics, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of HER2 ADC Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
T-DM1锛圞adcyla锛孴rastuzumab emtansine锛�
T-DXd锛圖S-8201锛孍nhertu锛孴rastuzumab deruxtecan锛�
RC48锛圖isitamab vedotin锛�
Segmentation by Application:
Hospitals
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Daiichi Sankyo
Genentech, Inc.(Roche)
AstraZeneca
RemeGen
MacroGenics
Takeda
Biokin Pharmaceutical
BioNTech(Yingen Biopharmaceutical)
CSPC Pharmaceutical Group
Hengrui Pharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global HER2 ADC Drugs market?
What factors are driving HER2 ADC Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do HER2 ADC Drugs market opportunities vary by end market size?
How does HER2 ADC Drugs break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global HER2 ADC Drugs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for HER2 ADC Drugs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for HER2 ADC Drugs by Country/Region, 2019, 2023 & 2030
2.2 HER2 ADC Drugs Segment by Type
2.2.1 T-DM1锛圞adcyla锛孴rastuzumab emtansine锛�
2.2.2 T-DXd锛圖S-8201锛孍nhertu锛孴rastuzumab deruxtecan锛�
2.2.3 RC48锛圖isitamab vedotin锛�
2.3 HER2 ADC Drugs Sales by Type
2.3.1 Global HER2 ADC Drugs Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global HER2 ADC Drugs Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global HER2 ADC Drugs Sale Price by Type (2019-2024)
2.4 HER2 ADC Drugs Segment by Application
2.4.1 Hospitals
2.4.2 Clinic
2.4.3 Others
2.5 HER2 ADC Drugs Sales by Application
2.5.1 Global HER2 ADC Drugs Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global HER2 ADC Drugs Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global HER2 ADC Drugs Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global HER2 ADC Drugs Breakdown Data by Company
3.1.1 Global HER2 ADC Drugs Annual Sales by Company (2019-2024)
3.1.2 Global HER2 ADC Drugs Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global HER2 ADC Drugs Annual Revenue by Company (2019-2024)
3.2.1 Global HER2 ADC Drugs Revenue by Company (2019-2024)
3.2.2 Global HER2 ADC Drugs Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global HER2 ADC Drugs Sale Price by Company
3.4 Key Manufacturers HER2 ADC Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers HER2 ADC Drugs Product Location Distribution
3.4.2 Players HER2 ADC Drugs Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for HER2 ADC Drugs by Geographic Region
4.1 World Historic HER2 ADC Drugs 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global HER2 ADC Drugs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global HER2 ADC Drugs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic HER2 ADC Drugs 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global HER2 ADC Drugs Annual Sales by Country/Region (2019-2024)
4.2.2 Global HER2 ADC Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas HER2 ADC Drugs Sales Growth
4.4 APAC HER2 ADC Drugs Sales Growth
4.5 Europe HER2 ADC Drugs Sales Growth
4.6 Middle East & Africa HER2 ADC Drugs Sales Growth
5 Americas
5.1 Americas HER2 ADC Drugs Sales by Country
5.1.1 Americas HER2 ADC Drugs Sales by Country (2019-2024)
5.1.2 Americas HER2 ADC Drugs Revenue by Country (2019-2024)
5.2 Americas HER2 ADC Drugs Sales by Type (2019-2024)
5.3 Americas HER2 ADC Drugs Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC HER2 ADC Drugs Sales by Region
6.1.1 APAC HER2 ADC Drugs Sales by Region (2019-2024)
6.1.2 APAC HER2 ADC Drugs Revenue by Region (2019-2024)
6.2 APAC HER2 ADC Drugs Sales by Type (2019-2024)
6.3 APAC HER2 ADC Drugs Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe HER2 ADC Drugs by Country
7.1.1 Europe HER2 ADC Drugs Sales by Country (2019-2024)
7.1.2 Europe HER2 ADC Drugs Revenue by Country (2019-2024)
7.2 Europe HER2 ADC Drugs Sales by Type (2019-2024)
7.3 Europe HER2 ADC Drugs Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa HER2 ADC Drugs by Country
8.1.1 Middle East & Africa HER2 ADC Drugs Sales by Country (2019-2024)
8.1.2 Middle East & Africa HER2 ADC Drugs Revenue by Country (2019-2024)
8.2 Middle East & Africa HER2 ADC Drugs Sales by Type (2019-2024)
8.3 Middle East & Africa HER2 ADC Drugs Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of HER2 ADC Drugs
10.3 Manufacturing Process Analysis of HER2 ADC Drugs
10.4 Industry Chain Structure of HER2 ADC Drugs
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 HER2 ADC Drugs Distributors
11.3 HER2 ADC Drugs Customer
12 World Forecast Review for HER2 ADC Drugs by Geographic Region
12.1 Global HER2 ADC Drugs 麻豆原创 Size Forecast by Region
12.1.1 Global HER2 ADC Drugs Forecast by Region (2025-2030)
12.1.2 Global HER2 ADC Drugs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global HER2 ADC Drugs Forecast by Type (2025-2030)
12.7 Global HER2 ADC Drugs Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Daiichi Sankyo
13.1.1 Daiichi Sankyo Company Information
13.1.2 Daiichi Sankyo HER2 ADC Drugs Product Portfolios and Specifications
13.1.3 Daiichi Sankyo HER2 ADC Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Daiichi Sankyo Main Business Overview
13.1.5 Daiichi Sankyo Latest Developments
13.2 Genentech, Inc.(Roche)
13.2.1 Genentech, Inc.(Roche) Company Information
13.2.2 Genentech, Inc.(Roche) HER2 ADC Drugs Product Portfolios and Specifications
13.2.3 Genentech, Inc.(Roche) HER2 ADC Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Genentech, Inc.(Roche) Main Business Overview
13.2.5 Genentech, Inc.(Roche) Latest Developments
13.3 AstraZeneca
13.3.1 AstraZeneca Company Information
13.3.2 AstraZeneca HER2 ADC Drugs Product Portfolios and Specifications
13.3.3 AstraZeneca HER2 ADC Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 AstraZeneca Main Business Overview
13.3.5 AstraZeneca Latest Developments
13.4 RemeGen
13.4.1 RemeGen Company Information
13.4.2 RemeGen HER2 ADC Drugs Product Portfolios and Specifications
13.4.3 RemeGen HER2 ADC Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 RemeGen Main Business Overview
13.4.5 RemeGen Latest Developments
13.5 MacroGenics
13.5.1 MacroGenics Company Information
13.5.2 MacroGenics HER2 ADC Drugs Product Portfolios and Specifications
13.5.3 MacroGenics HER2 ADC Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 MacroGenics Main Business Overview
13.5.5 MacroGenics Latest Developments
13.6 Takeda
13.6.1 Takeda Company Information
13.6.2 Takeda HER2 ADC Drugs Product Portfolios and Specifications
13.6.3 Takeda HER2 ADC Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Takeda Main Business Overview
13.6.5 Takeda Latest Developments
13.7 Biokin Pharmaceutical
13.7.1 Biokin Pharmaceutical Company Information
13.7.2 Biokin Pharmaceutical HER2 ADC Drugs Product Portfolios and Specifications
13.7.3 Biokin Pharmaceutical HER2 ADC Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Biokin Pharmaceutical Main Business Overview
13.7.5 Biokin Pharmaceutical Latest Developments
13.8 BioNTech(Yingen Biopharmaceutical)
13.8.1 BioNTech(Yingen Biopharmaceutical) Company Information
13.8.2 BioNTech(Yingen Biopharmaceutical) HER2 ADC Drugs Product Portfolios and Specifications
13.8.3 BioNTech(Yingen Biopharmaceutical) HER2 ADC Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 BioNTech(Yingen Biopharmaceutical) Main Business Overview
13.8.5 BioNTech(Yingen Biopharmaceutical) Latest Developments
13.9 CSPC Pharmaceutical Group
13.9.1 CSPC Pharmaceutical Group Company Information
13.9.2 CSPC Pharmaceutical Group HER2 ADC Drugs Product Portfolios and Specifications
13.9.3 CSPC Pharmaceutical Group HER2 ADC Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 CSPC Pharmaceutical Group Main Business Overview
13.9.5 CSPC Pharmaceutical Group Latest Developments
13.10 Hengrui Pharmaceuticals
13.10.1 Hengrui Pharmaceuticals Company Information
13.10.2 Hengrui Pharmaceuticals HER2 ADC Drugs Product Portfolios and Specifications
13.10.3 Hengrui Pharmaceuticals HER2 ADC Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Hengrui Pharmaceuticals Main Business Overview
13.10.5 Hengrui Pharmaceuticals Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.